CMS Ends Medicare Part D Subsidy Program, Citing Market Stability

The Centers for Medicare & Medicaid Services (CMS) has announced it will end the Medicare Part D Premium Stabilization Demonstration at the conclusion of the 2026 plan year. This program, which was first implemented in 2025, aimed to keep premiums low for beneficiaries by providing subsidies to insurance companies. The decision marks a significant shift in how the government supports prescription drug coverage for seniors and individuals with disabilities.

In a notice posted on Tuesday, CMS outlined key guidance for Part D plans as they prepare bids for the upcoming annual enrollment period. According to the agency, the subsidy program will be phased out by 2027, returning the market to what it describes as "traditional conditions." This move has raised concerns among advocates and some healthcare experts who worry about the potential impact on beneficiaries' out-of-pocket costs.

The End of a Controversial Program

The Premium Stabilization Demonstration was initially introduced to stabilize premiums in the Medicare Part D program, which covers prescription drugs for millions of seniors and people with disabilities. The subsidy was designed to help insurers manage the financial risks associated with offering these plans, particularly during a period when drug prices were rising.

However, CMS Administrator Mehmet Oz, M.D., has been vocal about his criticism of the program. In a statement posted to his X account, Dr. Oz said that the Biden administration had "given BILLIONS of taxpayer money DIRECTLY to Big Insurance Companies" through the subsidy. He argued that the subsidies led insurers to raise their rates, knowing that the federal government would cover the additional costs.

The CMS notice states that an analysis of bids from insurance companies suggests they now have sufficient experience with the redesigned Part D benefit to make informed decisions about their prescription drug plans without the need for subsidies. This confidence in the market's ability to function without federal support is a key factor in the decision to end the program.

What Comes Next

The base beneficiary premium for 2027 will be set at $41.33, according to CMS. Under the Inflation Reduction Act, this base premium cannot increase by more than 6% per year between 2024 and 2029. However, the end of the subsidy program may still lead to higher premiums for beneficiaries as insurers adjust to the new market conditions.

Full details on the current Medicare Advantage and Part D landscape, including average premiums, will be released in September. This information will provide a clearer picture of how the changes might affect beneficiaries' costs and coverage options.

The decision to end the subsidy program reflects a broader trend in healthcare policy where the government is stepping back from direct financial support and allowing market forces to play a more significant role. While this approach may lead to greater stability in the long term, it also raises questions about access and affordability for vulnerable populations.

As the 2027 enrollment period approaches, beneficiaries will need to carefully review their options and consider how the changes might impact their healthcare costs. Advocates and policymakers will be closely monitoring the situation to ensure that seniors and individuals with disabilities continue to have access to affordable prescription drug coverage.